Background: Stroke after left cardiac catheterization is infrequent but it represents the most debilitating complication from the patient perspective. Whereas the overall rate of adverse events declined over the last decades, the incidence of periprocedural stroke has remained unchanged. Ischemic stroke represents a high majority of symptomatic strokes and the potential mechanisms underlying these events include thrombus or air embolization, iatrogenic arterial dissection, hypotension and embolization debris of atheroma from the aortic wall. Given the devastating consequence, we sought to identify incidence, in-hospital outcomes and all modifiable and no modifiable risks factors of this adverse event in a high volume center. Methods: Our retrospective study included all patients experiencing periprocedural ischemic stroke among 24500 patients who underwent left cardiac catheterization between January 2003 and October 2010. The stroke group were compared with a case group control of 500 individuals randomized from the initial source population. Results: Ischemic cardiovascular events occurred in 46 patients (0.19% of procedures) and included transient ischemic attack (TIA) in 16 cases and stroke in 30 cases. Hospital stay was significantly prolonged (12.4 vs 8.2 days pϽ0.001) and the in-hospital mortality was higher (8.7% vs 0.6% pϽ0.001) in stroke group. On multivariate analysis, diabetes mellitus (adjusted odds ratio ¬(OR) 3,6; 95% confidence interval (CI) 1,7 to 7,7; pϽ0,001); chronic renal dysfunction (OR 2,4, 95% CI 1,1-5,4; pϽ0,001), known cerebrovascular disease (OR 7, 3, 8; pϽ0, 001) and recent congestive heart failure (OR 2,6, 95% CI 1,1-6; pϽ0,001) were independent predictors for stroke. The independent modifiable predictive factors were represented by left ventricular angiography (OR 5,6, 95% CI 2,2-13,8; pϽ0,001), emergent cardiac catheterization (OR 4,5, 95% CI 1,8-11,2; pϽ0,01) and low operator volume (OR 2, 7, 95% CI 1, 8; pϽ0, 01) . Conclusions: A really careful procedural planning taking account patients, procedural risk factors and operator experience might still actually decrease the incidence of this devastating complication.
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Long Background: The long-term clinical outcome of bulky covered stents in the percutaneous treatment of diseased saphenous vein graft (SVG) has been disappointing. However, the single self-expanding polytetrafluoroethylene (PTFE)-covered Symbiot stent with a unique profile, has not been evaluated and may present advantages that translate into superior long-term clinical outcomes. This study evaluated the safety, effectiveness and clinical outcome of the SymbiotTM covered stent system (Boston Scientific, Natick, Mass.) and FilterWireTM EX (Boston Scientific, Natick, Mass.) versus bare metal stents (BMS) in SVG intervention. Methods: Between January 2003 and August 2005, 90 patients with degenerative SVG lesions were prospectively randomized at 6 study sites to Symbiot implantation (nϭ30), BMS with FilterWire as embolic protection device (EPD, nϭ30), or BMS without EPD (control group, nϭ30). The primary endpoint was reduction in peri-procedural cardiac enzyme rise. The major secondary endpoints were in-hospital, 6 month and long-term target vessel failure (TVF) rates, defined as the cumulative of death, myocardial infarction and clinically-driven target lesion revascularization. (Table) , there were numerically less deaths in the Symbiot group, although this did not reach statistical significance (pϭ0.20). There was no significant difference in TVF-free survival between the treatment groups (pϭ0.98). 
Clinical Events at Longest

P O S T E R S
